Regenxbio Inc. announced a proposed underwritten public offering of up to $100 million in common stock and pre-funded warrants on Thursday [1, 2, 3].
Equity offerings often lead to short-term share price volatility because they increase the total number of shares available, which can dilute the value for existing investors. This move allows the company to secure significant capital for its operations but typically triggers a sell-off in the immediate aftermath.
The offering consists of approximately 10 million shares of common stock [2]. These shares are priced at $9 per share [2]. Additionally, the company is offering about 1.1 million pre-funded warrants, also priced at $9 per warrant [2].
Market reaction to the announcement was immediate. Shares of the company, which trades on the Nasdaq under the ticker RGNX, closed 8.7% lower on the day of the announcement [2]. However, reporting on the extent of the decline varies across financial news outlets.
One report indicated a 1.70% dip during post-market trading hours [1]. Other data suggests a more severe reaction, with shares falling 17% in after-hours trading to reach a price of $9.25 [3].
Regenxbio intends to use the gross proceeds from the sale of these securities to support its ongoing business goals [2, 1]. The company filed a prospectus to formalize the terms of the offering as it seeks to raise the $100 million total [1].
“Regenxbio announced a proposed underwritten public offering of up to $100 million”
The issuance of new shares and warrants is a common strategy for biotechnology companies to fund expensive research and development cycles. While the $100 million infusion provides a necessary capital cushion, the immediate market dip reflects investor concerns over equity dilution. The discrepancy in reported share declines, ranging from 1.70% to 17%, highlights the volatility and rapid price adjustments typical of after-hours trading following a capital-raising announcement.
